Genomtec is a technology company operating in the field of clinical diagnostics. It was established in 2016 in Wrocław, with a vision of international expansion based on a unique mobile genetic diagnostics platform utilizing a patented contactless heating and detection system. The company, founded by a group of scientists with experience and competences in the field of molecular biology, microstructures and photonics, has its headquarters and laboratories in Wrocław. Genomtec also has an office in the United Kingdom, where part of the international research and engineering team is located.
Genomtec S.A. is mainly involved in conducting research and development activities, as well as commercialization of its innovative molecular diagnostic products in the area of optical systems and isothermal nucleic acid amplification methods.
The company’s flagship project is Genomtec ID. Its creation and commeercialization will allow the diagnostic process to be executed in point of care setting, such as: primary care clinics, pharmacies, doctor’s offices, hospital emergency departments (ERs) without the need for complicated and time-consuming laboratory workflow conducted by qualified personnel. The main benefits of Genomtec ID are: small size of the analyzer, low energy consumption, shortened diagnostic time, wide spectrum and high accuracy of the analysis, as well as affordable price. All these features will put Genomtec ID ahead of other genetic diagnostic devices currently available on the global market.
Genomtec is also involved in the development and commercialization of laboratory tests for infectious diseases detection. The company thus meets the urgent need of fighting the COVID-19 pandemic caused by the SARS-CoV-2 virus.
According to the Management Board of Genomtec SA, the flagship product will be commercialised in the first half of 2022.
The COVID-19 pandemic has shown that rapidly determining the pathogenesis, or causes of the disease, at the level of basic cellular structures (RNA and DNA) is the new expected standard. Genetic diagnostics already offers the highest level of efficiency and precision in detecting pathogens. Upcoming epidemic challenges, such as, for example, subsequent epidemic cycles, rising treatment costs, aging population or rise in occurance of of neoplastic diseases have pushed the bar in the development of diagnostic technologies. Speed, efficiency and cost-effectiveness – these are the features that products available on the medical screening and diagnostic market should have in the near future. These expectations are met by new technological solutions, i.e. devices that allow conducting point-of-care testing (POCT).
Since its beginnings in 2016, the Genomtec team knew that rapid genetic diagnosis is the future of the market. In addition, the company chose to work with the new technology of Loop-Mediated Isothermal Nucleic Acid Amplification – LAMP..
It is an important part of the developed analyzer’s design based on the patented SNAAT®technology, consisting of photon energy contactless heating and temperature detection embedded in the analyzer system, which together with the microfluidic card and firmware creats the Genomtec ID mobile genetic diagnostics platform.
Significant events for Genomtec SA
Charudutt Shah appointed by Supervisory Board to join Genomtec Management Board starting August 1st, 2021.
Participation in person in Arab Health Show in Dubai, UAE.
Launch of newly registered in EU, the world’s first genetic diagnostic test for the detection of SARS-CoV-2 directly from a saliva sample Genomtec® RT-LAMP Direct Kit.
Genomtec successfully co-organizes science and educational conference: “New technologies in the laboratory of the COVID-19 pandemic” with 430 participants and 708 registered diagnosticians to promote RT-LAMP technology.
Designating 17 March 2021 as the first day of listing Genomtec SA shares on the NewConnect stock exchange trading floor.
Introduction of Genomtec shares to the alternative trading system on the NewConnect market pursuant to a resolution of the Warsaw Stock Exchange. As previously announced by the Company, the debut will take place in the first quarter of this year and is planned for March.
Krzysztof Krawczyk, Head of the Polish branch of CVC Capital Partners – a global leader in the private equity industry – joins Genomtec’s Supervisory Board. He is joined by Krzysztof Dębowski, who has worked for many companies in the hi-tech sector, and currently serves as the managing partner at KnowledgeHub Starter – one of the leading venture capital funds in Poland.
Genomtec took third place in the 2020 “Maker in China” competition, directly supported by the China-CEEC SME Research Institute Government Organisation, in which over 300 companies from Central and Eastern Europe and China compete.
Genomtec took second place in the 4th edition of the international competition “China Shenzhen Innovation & Entrepreneurship” for its Genomtec ID product beating over 1,000 other projects. The company received a cash prize of almost PLN 400,000 (RMB 650,000).
Genomtec produces first 5 prototypes of Genomtec ID. The complete prototype allows conducting required tests for the reaction card, to optimize thermal parameters and to reduce the time of individual stages during result processing. The team is also working on developing the service and user interface software, as well as an algorithm for repeatable and reliable handling of the final version of the reaction card with improved fluid flow rate. The work also involves optimization of the optical system for fluorescence detection, which was parameterized for reliable detection of spectral emission specific for the dye used. Further work will include verification of optical filters to obtain the best fluorescence signal-to-noise ratio.
Genomtec introduces a new product to the market, a two gene test for SARS-CoV-2 detection using RT-LAMP technology, CE-IVD labelled for sales throughout the EU. In-house analyses confirmed the effectiveness of the test for detecting new SARS-CoV-2 variants, i.e. British, South African and Brazilian variants, with mutations that can affect the efficacy of the genetic tests that are currently available on the market.
The company successfully placed all of its 730,000 shares on offer as part of its IPO, and obtained over PLN 8 million, which the company will allocate to the Genomtec ID platform, its preparation for marketing and mass production. The offer went to institutional and individual investors. The interest of investors significantly exceeds the number of shares that the Company could allot to them.
Patent application filed with the Patent Office of the Republic of Poland for Chlamydia trachomatis diagnostic kit: “A set of primers, reagent composition and a method for detection of atypical bacteria”.
Commencement of the historical, first public offering through which Genomtec plans to raise PLN 8 million for the further development of its flagship project, Genomtec ID.
The company receives the Money.pl Economic Award for the best technology of 2020.
Genomtec is granted a patent by the American Patent Office for the invention entitled “Method of detecting genetic material in a biological sample and a device for its implementation”.
Appointment to the Board of Michał Wachowski as Chief Financial Officer. Before joining the team, Michał was the investment director of the VC fund. A graduate of the Warsaw School of Economics in the field of Finance and Banking.
Appointment to the Board of Jarek Oleszczuk, former president of the board of the Polish branch of the global pharmaceutical company Astra Zeneca, and previously the general director of Abbott Laboratories Polska. As Chief Business Officer (CBO), Jarek is responsible for the further development and implementation of the company’s business strategy.
Genomtec receives nearly PLN 7 million (EUR 1.6 million) of funding from the National Centre for Research and Development (NCBiR) for its flagship project – a mobile molecular diagnostics system – Genomtec ID, which will be able to detect, among others, COVID-19 within 15 minutes. Genomtec was among the eight finalists of the competition, which were awarded co-financing under the 2014-2020 Smart Growth Operational Program, measure 1.1 under sub-measure 1.1.1 “Fast Track”. The total value of the project “Development of mobile diagnostic equipment for COVID-19 detection” amounts to almost PLN 11 million net (approx. EUR 2.4 million), including PLN 7 million (EUR 1.6 million) in funding from the National Centre for Research and Development.
Obtaining a certificate of free sale (number 434/2020) from URPLiMB (Office for Registration of Medicinal Products, Medical Devices and Biocidal Products), for the diagnostic kit Genomtec® SARS-CoV-2 RT-LAMP/N CE-IVD Laboratory Kit. The certificate of free sale is issued for a product labelled with CE (it is the manufacturer’s declaration that the product that has been placed on the market meets the essential requirements, as well as legal regulations, quality and safety standards regarding this product) and reported to the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in order to facilitate export. The document confirms that the product indicated therein, on the date of issuing the certificate, is or could have been marketed and used within the territory of the Republic of Poland.
Conclusion of a non-exclusive commercial cooperation agreement with Synektik S.A. concerning the distribution of SARS-CoV-2 tests developed by the Company in Poland. After the end of the initial period, i.e. 30 November, 2020, the terms of the contract negotiated by that time will enter into force, specifying the rules for further cooperation. The Agreement allows for the expansion of sales channels in Poland for the Company’s product lines, laboratory tests, and introduces active marketing of GNT (SNAAT®) technology in all channels used by Synektik S.A.
Obtaining patent protection on the territory of Poland for a patent application entitled “Method of detecting genetic material in a biological sample and a device for its implementation”.
Signing a conditional agreement with the UK-based CDMO company for the production of the Genomtec ID analyzer.
Obtaining the consent of the USPTO expert to receive a patent for the invention entitled “Method of detecting genetic material in a biological sample and a device for its implementation” in the USA, which is a significant step towards obtaining patent protection.
Filing two patent applications in the area of molecular biology under the name “Diagnostic Primers, Kits and Methods for Viral Detection” with the British Patent Office.
Filing an application with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for an invention entitled “Mycoplasma pneumoniae bacteria detection primer sets, Mycoplasma pneumoaniae infection detection method, Mycoplasma pneumoniae detection primer kit application” regarding small bacteria causing respiratory infections.
Patent application filed for a kit used in diagnosis of selected, most oncogenic human papillomavirus types: HPV 16 and HPV 18 (a virus responsible for cancer development, transmitted mainly during sexual intercourse or a direct contact with the skin of a virus carrier).
Genomtec signs a letter of intent with Astra Zeneca Pharma Poland concerning possibilities of commercial applications of the Company’s technology for diagnostics and personalized treatment of patients with non-small-cell lung carcinoma (NSCLC). It is one of the two main types of lung cancer, responsible for approx. 80% of cases.
Another patent application filed with the Patent Office of the Republic of Poland “Kit for contactless temperature control, method for generating electromagnetic radiation wavefronts and kit’s application for generating temperature field profiles” regarding the method of using electromagnetic waves for contactless heating, which has a broad range of industrial applications. Currently, the application is being processed at the EUIPO and local patent offices in China, Japan and USA.
Filing the first patent application in the field of molecular biology called “Primer kit for the detection of Borrelia burgdorferi, a method for the detection and diagnosis of Borrelia burgdorferi using a primer kit and kit for the detection of Borrelia burgdorferi” for bacteria that cause Lyme disease.
Filing a key patent application with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products under the name “Method of detecting genetic material in a biological sample and a device for its implementation”. Patent proceedings are pending at EUIPO and local patent offices in Canada, China, Japan and Brazil.
The co-founder and leader of Genomtec. His responsibilities within the company involve, among others, R & D and development of innovative diagnostic devices. A graduate of the Faculty of Pharmacy and Clinical Laboratory Sciences Unit at Wroclaw Medical University, a PhD student in the field of molecular biology, laboratory diagnostician. Author of a number of scientific publications and the co-author of Genomtec patents. Ambitious and young, but already an experienced scientist. He has won a number of awards and honors for his master’s thesis. Head of a research project for the National Science Center.
At Genomtec, in addition to managing the company, Miron actively participates in R&D in the field of molecular biology in the area of infectious diseases.
Michał has over 14 years of experience in the area of corporate finance, investment management and business consulting. Before joining the team, he was an investment director in an actively investing Venture Capital fund. Previously, he was a member of the Management Board of a medium-sized production company in the energy sector and Vice President, Finance in a start-up in the chemical industry. He has advised on a number of transactions in the field of investments, mergers and acquisitions, as well as restructuring processes. Previously, he held operational positions at ARP, TFS, Deloitte, Polimex-Mostostal and Central Europe Trust. He holds a Master’s degree from the Warsaw School of Economics in the field of Finance and Banking and has completed postgraduate studies in Information Technology Transfer to Enterprises.
At Genomtec, he is responsible for the company’s finances.
Charudutt is a senior executive with many years of international experience, incl. in the area of business development, marketing and sales management and strategic planning in the clinical genetic diagnosis sector. He will start work at Genomtec on August 1, 2021. He has several years of leadership experience in the area of product commercialization, brand development and partnership with international entities. A major focus of his efforts are in developing go to market strategies, driving clinician awareness, market access and bringing innovative testing solutions to various healthcare ecosystems to improve patient care.
Charudutt is a graduate of the University of Toronto and holds both a Bachelors of Applied Science and Engineering degree as well as a Masters of Biotechnology and Management degree. He also holds a certificate of Alliance Management from the Canadian Healthcare Licensing Association.
Jason has a degree in medical electronics from the Engineering Department of the University of Kent at Canterbury, bringing to Genomtec more than 30 years of experience in the design and manufacture of medical and scientific devices. He has worked with leading universities and companies around the world as a consultant, including: Varex Imaging, Perkin Elmer and Novartis. His services as a consultant were used by companies and institutions such as: Pfizer, Infineon, Oxfort Instruments, Atmel and the Institute of Metabolism Sciences of the University of Cambridge.
At Genomtec, he is responsible for the research and development of innovative diagnostic devices, planning and organisation of the work of the research engineering team, development of quality and document management systems, and consulting in the field of personnel policy for the technical team.
Małgorzata is a graduate of the Medical University of Wrocław and a laboratory diagnostician. She received the title of doctor of medical sciences in December 2010. She has over 10 years of experience in the field of molecular biology. She is a specialist and expert in the field of INNAT (Isothermal Nucleic Acid Amplification Technology) molecular technologies. She has completed numerous workshops and research internships, including at the Joslin Diabetes Center, Harvard Medical School in Boston. In 2011-2013, she was employed as an assistant professor at the Laboratory of Cell Signals and Metabolic Disorders at the Institute of Experimental and Cell Biology at the Polish Academy of Sciences in Warsaw. Since 2010 she has been working as an scientific researcher at the Department of Molecular Techniques of the Medical University in Wrocław, and since 2015 as an assistant professor. Author of scientific publications and co-author of Genomtec technologies and patents.
At Genomtec, she is responsible for managing the molecular biology team and implementing new solutions in the field of genetics and diagnostic processes for innovative products.
Coordinator of R&D activities in the areas of the analyzer and diagnostic reaction cards. An expert at the Wroclaw University of Science and Technology at the Faculty of Microsystem Electronics and Photonics, a versatile, talented electronics engineer and a designer of advanced electronic devices. He co-created such devices as the portable X-ray source “Photon Needle” for medical applications for the Institute for Nuclear Studies in Świerk, a 300 W plasma generator for technological processes in the SECON device at the Institute of Electron Technology in Warsaw or IV Measurement Systems (Photoemission Tech, Inc. Camarillo US). An author of patents and over 80 domestic and foreign scientific publications. He was awarded the title of the second lieutenant of the Polish Armed Forces in the Central Training Center of Technical Specialists of the Air Force.
At Genomtec, he is responsible for coordination and implementation of technical solutions for the analyzer and diagnostic reaction cards.
Bolesław received his Master’s degree from the University of Silesia (Faculty of Biology and Biotechnology), and his PhD from the Medical Academy of Exeter University (Institute of Biomedical and Clinical Research). He also holds a project management certificate from the PMP Project Management Institute. Bolesław has gained professional experience in the field of sales processes (pharmaceutical industry), research in the biomedical sector (oncology and pharmacology), and working with patients participating in biomedical research in the National Health System in England. While working at the Regional Development Agency on behalf of the local government in Greater Manchester and the Dept. for International Trade (UK DIT) as a manager, he was responsible for attracting investments from bio-tech and med-tech companies, advising on the process of strategic relocation of companies, and also by supporting them in accessing scientific, medical, investment and government institutions, as well as the real estate market.
At Genomtec, he is responsible for the development of product commercialization strategies, registration activities on international markets and products’ validation studies, and development of distribution networks for the Company’s solutions.
Magdalena is a senior manager specializing in marketing and communication, including investor relations and the organization of international events with the participation of representatives of governments and global institutions. She worked as a managing director in the PZU Group and vice president of PZU Pomoc. Previously, as the director of marketing communication for the region of Europe, the Middle East and Africa at Arysta Lifescience and a member of the management board of LafargeHolcim in Poland.
For 7 years she was responsible for corporate communication in the American giant DuPont in Central Europe (21 countries). She also worked for Mostostal-Export (4 years) and Polish Securities and Exchange Commission.
A graduate of the National Louis University in Chicago and the Warsaw School of Economics.
Matylda is a graduate of the Medical University of Wrocław and a laboratory diagnostician with experience in the field of molecular biology. Author of scientific publications, she has conducted many research projects and coordinated clinical trials. In recent years, she has carried out her research work at the Department and Clinic of Neonatology, dealing with the nutritional aspect and biological activity of breast milk, while coordinating the Regional Bank of Breast Milk at the University Clinical Hospital in Wrocław. Expert in research on DNA and RNA of pathogens.
At Genomtec, she supports research and development in the field of molecular biology, managing the laboratory in Wrocław.
A graduate of mechanical engineering from Brunel University London. A chartered member of the Institution of Mechanical Engineers, with over 30 years of continuous design and development experience with a mechanical and electromechanical bias, primarily within the instrumentation, medical device and process equipment industries, but also with early career experience in the high volume automotive ancillary equipment industry. Familiar with working in and often leading multidisciplinary teams to produce new products from concept through to full production. Readily able to work both at strategic (director/manager) and detailed (practitioner engineer) levels, generating ideas to meet customers’ needs and turning these ideas into commercial reality. Instrumental in introducing engineering standards and quality systems into the work environment and managing the impact associated with growth and change.
Lee is an experienced mechanical/production engineer with a long career in engineering design and management. Starting his career in medical instrument design with responsibility for leading multifunctional engineering teams. Progressing into senior engineering management taking on an engineering directorship with a company in the security sector.
He works for Genomtec from the UK office.
A Mechanical Engineer with over 30 years experience and an MSc in engineering management. Started his career as a cadet Engineering Technologist specialising in instrumentation, design and manufacturing. Has worked for a variety of organizations in roles ranging from Design Engineer through to Operations Manager. Les spent the last 14 years working on product research and development in the Aviation sector. Has 5 patents relating to product design and won the 2019 ‘Best MSc Project’ at the University of Greenwich.
He works for Genomtec from the UK office.
Mathew has over 15 years of experience engineering in a diverse range of fields from the oil and gas industry to medical devices. A highly adaptable engineer who takes time to develop a holistic view of a product’s development but specializes in Embedded Software. He has experience across the product life-cycle from concept to production, in a range of companies from small start-ups to multinational household names. Mathew is equally at home coding multi-threaded embedded software for high level operating systems, and low-level code running on bare metal microcontrollers. Mathew is a graduate of Sussex University with a Masters in Computer Systems Engineering.
Katarzyna is a graduate of the Lodz University of Technology, Faculty of Biotechnology and Food Sciences, majoring in biotechnology and specialising in technical biochemistry. She has professional experience in conducting and coordinating research projects. In the years 2004-2007 as a fellow she conducted research at the University of Virginia in Charlottesville. In 2011-2018, at the Wrocław Research Center EIT +, she worked in the area of international cooperation, with particular emphasis on the Polish-American partnership, and was responsible for implementing the business model, expansion strategy, customer acquisition, maintaining business relations and coordinating research orders. She is the author and co-author of scientific publications.
At Genomtec, Katarzyna is responsible for conducting and coordinating research projects, mainly from the European Union, and for supervising the IP strategy. She takes part in research projects.
Irena is a laboratory diagnostician and a doctor of medical sciences in the field of molecular biology. For years she has been working for the Faculty and Department of Oral Pathology at Wrocław Medical University. She gained professional experience working as an embryologist and managing medical teams. She is the author of the Scientific News section in the montly journal Medical Tribune Stomatology. She gained research and teaching experience in European research institutions, including in Italy, Germany and Lithuania. Privately, she enjoys art house cinema.
At Genomtec, she is responsible for coordinating molecular biology activities in the SARS-CoV-2 virus diagnosis sector.
Aneta is a graduate of the Faculty of Pharmacy with the Department of Analytical Medicine at the Medical University of Wrocław. She is a trained laboratory diagnostician. Currently, she is in the process of completing her doctoral studies in the field of molecular biology at the Department of Molecular Techniques, Medical University in Wrocław. Author of scientific publications, she has also collaborated on several research projects.
At Genomtec, Aneta supports research and development in the field of molecular biology, and coordinates the work of the production department.
Aleksander Szymczak received his Master’s degree in Microbiology with a specialization in Immunology, from Dept. of Medical Microbiology and Laboratory Diagnostics at the University of Lodz. He is currently working on his PhD at the Bacteriophage Laboratory of the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences. There he conducts research in the field of genetics and metagenomics concerning the human microbiome. Since 2019, he has been leading the Preludium 16 project of the National Science Centre.
At Genomtec, Aleksander deals with the bioinformatics analysis of data.
The alumnae and PhD student at Faculty of Microsystem Electronics and Photonics at Wroclaw University of Science and Technology. A specialist in the field of microelectronics, sensors and fluidic microsystems and microplasma generators. His research work is focused on development of the miniature sensors utilizing optical detection.
At Genomtec, he is responsible for selection of electronic components, material testing and research and development of Genomtec ID.
A graduate of Biomedical Engineering and Electronics at the Wrocław University of Technology. His professional interests are sensors, signals and PCB design.
He has gained experience in the field of engineering, among others, on the design of a bionic prosthesis and, after moving to Belgium, on the design of a remotely controlled base station for the army.
At Genomtec, he is responsible for electronic design, device development and R&D. In his spare time, he composes music, plays instruments and constructs audio devices.
PhD in technical sciences, electronics, specialist in microelectronics, electronic and photonic materials engineering, sensors and transducers. A graduate of the Faculty of Microsystem Electronics and Photonics of the Wrocław University of Technology. Author of numerous scientific publications and patents. Contractor in research projects financed from public funds and industry.
At Genomtec he is responsible for the design of electronic circuits and tests of materials used to build the Genomtec ID device.
A graduate In Microsystem electronics and Photonics at the University of Science and Technology in Wroclaw. His professional specialization includes embedded systems in various applications, especially within the software fields. Enthusiast of the science, fascinated by artificial intelligence systems. He started his adventure with devices from the medical/biotechnology category during his studies – the winner of the best diploma thesis at the faculty.
His duties at Genomtec include the development of device and software architecture, the implementation of new solution, as well as general research and development.
At Genomtec, he coordinates all R&D activities and oversees the work of the technological and biological-molecular team.
Professor Dobosz is a co-creator of the Genomtec technology, an outstanding Polish scientist with almost 50 years of scientific experience, and a widely recognized specialist in the field of clinical genetics. His scientific activity began at the Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences in Wrocław. Since 2004 he has been the head of the Molecular Techniques Unit at the Department of Forensic Medicine of the Wroclaw Medical University. He’s the author of 56 printed works occupying a spot on the ISI Master Journal List and over 470 scientific publications. The creator of many improvement and patenting proposals. Winner of 14 different prizes, including the Gold Cross of Merit, awarded for his achievements in the introduction of DNA testing technology to Polish forensic genetics, and the Knight’s Cross of the Order of Polonia Restituta. He was a part of two international teams of experts under the Society for Forensic Haemogenetics.
He has served multiple times as a technical auditor for the Polish Center for Accreditation.
She received the title of doctor of medical science at the Faculty of Medicine of the Wrocław Medical University. Currently, she is an adjunct professor at the Department of Microbiology at the Institute of Genetics and Microbiology of the University of Wrocław. Vice-president of the Wrocław Branch of the Polish Society of Microbiologists.
Eric Garnier has an experience of around 35 years in healthcare businesses, including 12 years of expatriation in the UK, Asia and the US. During this period, Eric has occupied key positions with increasing responsibilities in two American multinational Life Sciences companies i.e., Bristol-Myers Squibb and Pall Corporation (a Danaher company).
Eric started in finance and has had several management roles in France and in the UK as European Finance Director in Bristol-Myers Squibb. He subsequently moved to general management leadership positions as General Manager France, Regional VP South Europe and then President of the AsiaPac region for Pall, a $800M business, based in Singapore. In his last role with Pall Eric was Vice President and GM of the global Medical BU based in Boston.
After having relocated back to France in 2018 Eric has set up his own consultancy business specializing in healthcare. He is also a member of the board of Angels Santé, has invested in more than 20 start-ups and is a board member in a few of these. Eric has an MBA from Institut Superieur de Gestion (Paris).
Krishnendu Chakrabarty received the B. Tech. degree from the Indian Institute of Technology, Kharagpur, in 1990, and the M.S.E. and Ph.D. degrees from the University of Michigan, Ann Arbor, in 1992 and 1995, respectively. He is now the John Cocke Distinguished Professor and Department Chair of Electrical and Computer Engineering (ECE), and Professor of Computer Science, at Duke University. He has held Visiting Professor positions and Chair Professorships at University of Tokyo (Japan), University of Bremen (Germany), Tsinghua University (China), National Tsinghua University (Taiwan) and National Cheng-Kung University (Taiwan). He has been awarded with multiple awards and scholarships all over the globe.
Prof. Chakrabarty’s current research projects include: design-for-testability of integrated circuits and systems (especially 3D integration and system-on-chip); microfluidic biochips; hardware security; machine learning for fault diagnosis, failure prediction, healthcare, and biochemical analysis; neuromorphic computing systems. His research has been supported by the National Science Foundation, DARPA, Office of Naval Research, National Institutes of Health, Army Research Office, Semiconductor Research Corporation, and directly by companies such as Intel, Cisco, and HP. He has published 26 books (with one book translated into Chinese) and over 800 peer-reviewed papers on these topics. He holds 18 US patents (with) two patents pending) and his research on microfluidic biochips has been licensed by Advanced Liquid Logic, Illumina, GenMark, and Baebies Inc. His test technology solutions have been adopted by Intel, TSMC, Samsung, Mentor Graphics (now part of Siemens), and Qualcomm. He has supervised 36 PhD dissertations.
Prof. Chakrabarty is a Fellow of ACM, a Fellow of IEEE, a Fellow of AAAS, a Golden Core Member of the IEEE Computer Society, and a Senior Member of the National Academy of Inventors. He was a Distinguished Visitor of the IEEE Computer Society (2005-2007, 2010-2012), a Distinguished Lecturer of the IEEE Circuits and Systems Society (2006-2007, 2012-2013), and an ACM Distinguished Speaker (2008-2016). Prof. Chakrabarty served as the Editor-in-Chief of IEEE Design & Test of Computers during 2010-2012, ACM Journal on Emerging Technologies in Computing Systems during 2010-2015, and IEEE Transactions on VLSI Systems during 2015-2018. He is an Associate Editor of IEEE Transactions on Biomedical Circuits and Systems. He has served in the past as an Associate Editor of IEEE Transactions on Computers, IEEE Transactions on Multiscale Computing Systems, IEEE Transactions on Computer-Aided Design of Integrated Circuits and Systems, ACM Transactions on Design Automation of Electronic Systems, IEEE Transactions on Circuits and Systems I, and IEEE Transactions on Circuits and Systems II. He has also served as General Co-Chair (2014, 2019) and Program Co-Chair (2005) of the IEEE Asian Test Symposium.
Genomtec took third place in the 2020 “Maker in China” competition, directly supported by the China-CEEC SME Research Institute Government Organisation, in which over 300 companies from Central and Eastern Europe and China compete. Genomtec ID is attracting the attention of Chinese investors, and the company is reassured that its efforts will be backed by the Chinese government’s anticipated expansion in that market at the local and central level.
Genomtec took second place in the 4th edition of the international competition “China Shenzhen Innovation & Entrepreneurship” and received an award of RMB 650,000 RMB, which is about PLN 400,000. Its innovative Genomtec ID platform beat out international competition with 1,046 projects entered. This win opens up new business and development opportunities on the Chinese market for the Company.
Genomtec wins the “Next Health Investment Pitch” competition organised for Polish companies who want to define economic reality through their innovations via Amgen and ImpactCEE. Amgen has been an international pioneer in biotechnology since 1980 and one of the world leaders in the production of biological medicines.
Genomtec won the “Start Up Med” competition organised by the 4th Health Challenges Congress, a forum for a multi-topic discussion on key issues for healthcare systems in Europe.
Genomtec was one of the five finalists of “InCredibles” – an acceleration program aimed at the most innovative and promising entrepreneurs organised by Kulczyk Investments.
Genomtec won second place in the “Shark Tank” competition organised by New Frontiers in Interventional Cardiology, during an international educational and industry meeting for representatives of medicine and related fields in cardiology, surgery and cardiac/vascular imaging.
Genomtec received a distinction in the “Eagle of Innovation” competition organised by Rzeczpospolita in the category of product and service innovations. In this competition, Rzeczpospolita honours young companies – start-ups – that offer innovative and value-creating products or services.
Genomtec took 1st place as the best non-US start-up participating in HUBweek, an annual innovation festival held since 2014 by The Boston Globe, Harvard University, Massachussetts General Hospital, which brings together the most creative minds that influence art, science, and technology.
Genomtec received a distinction in the competition “Architects of Innovation” in the category of “emerging technologies”, which aims to distinguish companies and institutions that focus on innovative solutions, enter new markets, and are not afraid to be a precursor of new trends.
Genomtec received a distinction in the competition “Architects of Innovation” in the category of “emerging technologies”, which aims to distinguish companies and institutions that focus on innovative solutions, enter new markets, and are not afraid to be a precursor of new trends.
Genomtec was one of the finalists of the Biomed PFR Academy, an educational initiative for innovative pharmaceutical and medical companies.
Miron Tokarski, co-founder and CEO of Genomtec was included on the “Forbes: 30 under 30” list, composed of the most promising young entrepreneurs, innovators, investors, managers, economists and business activists in Poland.
Genomtec won the “CVC Young Innovator Awards” competition organised by MIT Enterprise Forum Poland in the acceleration program for start-ups from Central and Eastern Europe in collaboration with MIT and world leading investment funds, such as CVC Capital, dynamically supporting the company’s development.
Genomtec received the main “Innovation Initiator” award in the “Start-up” category from Newsweek Polska in a competition rewarding and promoting companies and institutions for whom innovation is the primary goal.
Genomtec won a bronze medal in the “Pitch to London” annual competition for the best start-ups from Poland, during which they had the opportunity to present themselves to British experts and investors.
Miron Tokarski ranked 9th among the “Top 50 Creative People in Business”, a year-round program involving the exchange of knowledge, experience and business opportunities, rewarding managers for innovation and unconventional solutions in their business.
Miron Tokarski wins the 2nd edition of the “Young Talents” competition in the “Success in innovation” category organised by the Lower Silesian Capital Club. The “Young Talents” competition aims to promote and appreciate young scientists and students from Lower Silesia who have achieved significant success.
The global market for molecular diagnostics is worth over USD 14 billion. COVID-19 has significantly increased it. It is estimated that in 2024 the value of the genetic diagnostics market may even reach USD 18 billion.
Part of this market is point-of-care (POC) molecular diagnostics on which Genomtec ID focuses. It is growing dynamically, with an average annual increase of over 14% y-o-y. In 2024, the global market for genetic diagnostics in point-of-care is expected to be worth nearly USD 4 billion.
The demand for this type of platform is very high. Genomtec ID is to provide patients with precise diagnostics and treatment at the first point of contact with health services, such as: primary care clinics, doctor’s offices, hospital emergency departments (ERs), ambulances or even pharmacies, without the need for complicated and time-consuming laboratory services conducted by qualified personnel. Importantly, due to concerns about the transmission of infections while traveling, our system can be successfully used, for example, at airports.
During Genomtec ID inception, we wanted to ensure universal and quick access to molecular analysis in places as close to the patient as possible.
The Genomtec ID Platform offers a number of prospective use-cases in many areas of medical diagnostics, including respiratory infections, STDs, and, in the future, also liquid biopsy and protein biomarker tests. The system consists of an analyzer and microfluidic reaction card employing lab-on-chip system, which allows simultaneous identification of up to 5 diagnostic targets.
Genomtec ID will be a world-wide unique diagnostic solution providing many advantages. The compact size of the device makes it mobile, which is of great importance. Genomtec ID fits onto a palm, which means it also does not take much space in a clinic, consulting room, ambulance, or emergency room.
The system is characterized by its speed of analysis, providing results as fast as in 15 minutes while maintaining test parameters (i.e., sensibility, repeatability, and specificity) at levels so far only reserved to laboratory genetic diagnostics.
The Genomtec ID platform is currently in the industrialization phase, i.e. adapting individual elements of the platform to mass manufacturing. This means the production of all the tooling, the integration of subassemblies and performing the necessary tests of the analyzer, e.g. electromagnetic and environmental. The device will be commercialized in the first half of 2022.
The development and production process is carried out in close cooperation with international companies with very extensive experience.
In the field of designing and manufacturing of the Genomtec ID analyzer, we are working with the UK-based Contract Development and Manufacturing Organization (CDMO), which is part of a large international organisation operating in the USA, Great Britain and China.
In the field of design and production of the reaction card, our partner is Microfluidic ChipShop GmbH, based in Jena, Germany. Microfluidic Chipshop GmbH has been established in 2002, specialising in the design and production of lab-on-chip solutions, i.e. miniaturized analytical devices using microfluidic technologies and electromechanical microelements.
Cooperation with international entities with an extensive experience increases the certainty of the project development process and gives us credibility in the eyes of large medical companies, which may be recipients of our device in the future.
The team working on Genomtec ID is international and consists of both Polish and foreign specialists with extensive experience in the implementation of similar projects in global medical devices companies.
The Genomtec ID platform is currently in the industrialization phase, i.e. adapting individual elements to mass manufacturing. This means the production of tooling, the integration of subassemblies and the performance of necessary analyzer tests, e.g. electromagnetic and environmental. So far, we have conducted intra-laboratory tests of the platform to optimise the individual components of the analyzer and the microfluidic card.
According to the plan, the industrialization phase of Genomtec ID will end in the fourth quarter of this year, and then the contracted pilot manufacturing with the company’s partner will comence.
Between 2021 and 2022, Genomtec ID will enter the phase of clinical performance studies in Poland and abroad. This is to facilitate the Company’s system certification procedure also on markets outside the European Union.
The tests must be performed almost on the final version of the device. Completion of the comparative study will allow for certification, and the commercialization of the device will take place in the mid-2022.
The Genomtec team is developing and commercializing other laboratory tests that can be used to detect infectious diseases e.g., of viral origin. This way, the Company responds to the current urgent need related to the ongoing fight with COVID-19 pandemic caused by SARS-CoV-2.
Currently Genomtec offers a product line of diagnostic laboratory tests for detecting SARS-CoV-2 in clinical samples.
Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE-IVD Duo Kit is a CE-IVD laboratory kit for qualitative detection of SARS-CoV-2 RNA in nasopharyngeal and oropharyngeal swabs from patients with suspected COVID-19. The product contains controls and reagents for reverse transcription and amplification of virus nucleic acid utilizing LAMP isothermal reaction. One kit allows for conducting 50 reactions (including control and sample reactions).
The studies on two-gene test, Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE-IVD Duo Kit showed that it can detect all three new SARS-CoV-2 virus strains (British, South African and Brazilian) with the same high precision as in case of the original virus strain. The production of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland and they are distributed nationally by Synektik.
At Genomtec, everything you do translates into a quick diagnosis that has an impact on people’s lives. We are a company with a flat organisation structure, where everyone can talk to each other, and the decision-making process is transparent and consulted with Team Members. We do not implement development levels, we abolish them in order to develop ourselves and our technology in the spirit of an interdisciplinary and international team, helping patients obtain a quick and accurate diagnosis.